General Requirements | Fees | Partial
Refunds | Education
Requirements | Examination
Requirements | Limited Permits | Applicants
Licensed in Another State | Dental
Any use of the title “Dental Hygienist” within New York
State requires licensure.
To be licensed as a dental hygienist in New York State you must:
- be of good moral character;
- be at least 17 years of age for dental hygiene licensure by
examination; be at least 21 years of age for licensure by endorsement
of another state’s license;
- meet education and examination requirements; and
- have satisfactorily practiced for at least two years for licensure
You must file an application for licensure and the other forms
indicated along with the appropriate fee, to the Office of the
Professions at the address specified on each form. It is your responsibility
to follow up with anyone you have asked to send us
Hometown Health Centers Dental Providers:
- Rory Schmit, DDS – Chief Dental Officer
- Sinah Abdullah, DDS
- Mohammed Khair, DDS
- Barry Loffredo, DDS
- Trevor O’Neil, DDS
- Henry Perry-Friedman, DMD
- Gurinder Wadhwa, Oral Surgeon
- Roxanne, Baugh, Hygienist
- Theresa Crowder, Hygienist
- Karen DeThorne, Hygienist
- Elise LeMay, Hygienist
- Margaret Gray, Hygienist – Dental Outreach
- Jana Pasquerella, Hygienist – Dental Outreach Manager
We provide a full range of on-site primary and preventative dental services to you and your family, including pediatric dental and oral health services.
HHC will counsel you on the necessity of accessing preventative dental care. You will be provided with information on available services, the importance of dental care and its relation to other underlying health care issues.
Our dental outreach team visits 17 schools across Schenectady County in a program highly acclaimed by the
Saudi Gazette report
MANAMA — Bahrain’s National Health Regulatory Authority (NHRA) has approved REGN-COV2 for emergency use, a new drug by Regeneron in collaboration with F. Hoffmann-La Roche, for the treatment of mild to moderate COVID-19 cases, the Bahrain News Agency reported on Wednesday.
REGN-COV2 contains a combination of Casirivimab and Imdevimab, which are drugs called “monoclonal antibodies,” that are designed to block viral attachment and entry into human cells to neutralize the virus.
REGN-COV2 also received emergency use approval from the US FDA to treat mild to moderate symptoms of COVID-19 in non-hospitalized adults and adolescents of 12 years of age and older, who weigh at least 88 pounds (40 kg), and for those who are at high risk for developing severe COVID-19 symptoms or of hospitalization.
REGN-COV2 also received a positive review from the European Medicines Agency after their analysis of the quality, safety, and efficacy aspects of